6 May 2026
In plain English
Quiet Tuesday. All seven forecasts holding. The most notable signal sitting outside the active forecast set: Novo Nordisk (the maker of Ozempic and Wegovy) filed for FDA approval of CagriSema — a next-generation combination weight-loss drug that achieved 22.7% body weight loss in its main trial, nearly 50% more effective than Wegovy alone. An FDA decision is expected around October. If approved, it reshapes the competitive landscape for every weight-loss product The Compound covers.
Closer to home: Hims & Hers (the telehealth company betting on peptides) reports earnings in five days. Estrogen patch shortages continue with no relief in sight — prescriptions have jumped 184% since 2023. The FDA's peptide advisory panel remains at three members out of twelve authorized, with 78 days until its July 23 meeting.
Signal detail
78 days to PCAC. Zero vacancy appointments in 11+ weeks. No new evidence. Public comment deadline July 9. Orrick's May 2026 legal analysis of the 503B GLP-1 exclusion confirms career FDA staff remain active on compounding oversight — tangential to PCAC but reveals institutional conservatism persists alongside political reclassification momentum.
Same vacancy dynamics. No new safety dossier submissions or USP monograph progress for any of the four peptides under review. Oral presentation deadline June 30 is the next signal-rich window.
5 days to May 11 Q1 earnings. Subscriber base growing 13% YoY, revenue per subscriber $83/mo. Manufacturing facility operational. Analyst EPS expected $0.06 (down 70% YoY). Watch for: peptide launch timeline specifics, California facility capex, and longevity specialty SKU details in the call.
No new adverse events. The 503B exclusion rationale disclosed centralized safety data: 455+ adverse events on compounded semaglutide and 320+ on compounded tirzepatide, many involving dosing errors from multi-dose vials requiring hospitalization. Not peptide-specific, but establishes a compounding-safety narrative template that post-PCAC media could adopt for peptide coverage.
56 days to July 1 launch. CMS operational silence continues — "spring 2026" design details promised but not delivered. Bridge-eligible drugs confirmed: Foundayo, Wegovy (injection and oral), Zepbound KwikPen.
Math structural and unchanged. GLP-1 CPA dominance ($260 vs $8-40) is durable.
86 days remain with zero build progress since forecast creation April 19 — now 17 days. GHK-Cu ($370M market) and HRT comparison remain fastest-build candidates. Execution constraint, not demand constraint.
How Barque got smarter today
- CagriSema surfaces a coverage gap. Seven active forecasts, none tracking the biggest GLP-1 pipeline catalyst of 2026. If coverage (the fourth resolution metric) matters, this gap should close. The candidate is high-confidence/low-novelty — structurally similar to Case 3 in historical-cases.md (tirzepatide approval, Brier 0.0225) — but its downstream effects on GLP-1 Picks content and provider economics are material.
- 503B exclusion safety data as narrative template. The FDA's disclosure of 455+ adverse events from compounded semaglutide provides sourced material for post-PCAC peptide safety framing. If PCAC opens peptide compounding in July, media will draw the analogy: "compounded peptides could repeat the compounded GLP-1 safety problems." This was implicit; now it is sourced with specific numbers.
- Hims pre-earnings information desert is normal. Five days before earnings with no leaks or pre-announcements is typical SEC quiet-period behavior. Do not mistake absence-of-signal for negative signal.
- Sources sampled. Tier 1: FDA.gov (PCAC roster, calendar, 503B proposal), CMS.gov, SEC EDGAR, Novo Nordisk IR, Eli Lilly IR, Orrick, Nat'l Law Review, BioSpace, PharmExec, FiercePharma, Drugs.com, STAT. Tier 2: KJZZ, The Hill, PBS (estrogen shortage coverage), Cornell Vet, Healthline. Reddit r/peptides and r/Menopause attempted — access blocked; fell back to search-derived community summaries.